All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
All‐cause mortality · persons with type 1 diabetes mellitus
Intensive glucose control showed no clear difference in all‐cause mortality compared with conventional glucose control (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with type 2 diabetes mellitus
Intensive glycaemic control showed no clear difference in all‐cause mortality compared with conventional glycaemic control (moderate certainty).
All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
All‐cause mortality · Older adults, 50 years and older
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in all‐cause mortality compared with continuation (low certainty).
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality1 · people with unprovoked VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).
1 finding from 1 review
All‐cause mortality · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events—all‐cause mortality · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
All‐cause short‐term mortality: at intensive care unit · adults with cardiogenic shock
It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes all‐cause mortality compared with morning dosing regimen (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with diuretic (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ACE inhibitor (low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ARB (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with β‐blocker (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with primary hypertension
Renin inhibitors showed no clear difference in all‐cause mortality compared with ACE inhibitors (low certainty).
1 finding from 1 review
All‐cause mortality · pulmonary hypertension in neonates
Sildenafil may leads to lower all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review